[go: up one dir, main page]

MX2007013327A - Formulaciones de liberacion prolongada. - Google Patents

Formulaciones de liberacion prolongada.

Info

Publication number
MX2007013327A
MX2007013327A MX2007013327A MX2007013327A MX2007013327A MX 2007013327 A MX2007013327 A MX 2007013327A MX 2007013327 A MX2007013327 A MX 2007013327A MX 2007013327 A MX2007013327 A MX 2007013327A MX 2007013327 A MX2007013327 A MX 2007013327A
Authority
MX
Mexico
Prior art keywords
release formulations
prolonged release
extended release
formulation
active ingredient
Prior art date
Application number
MX2007013327A
Other languages
English (en)
Inventor
Shubha Chungi
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MX2007013327A publication Critical patent/MX2007013327A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se refiere a una formulacion de liberacion prolongada que contiene un ingrediente activo pobremente soluble en agua, y a un metodo para preparar la formulacion. La formulacion contiene un material de liberacion prolongada basado en cera, que proporciona la liberacion prolongada del ingrediente activo.
MX2007013327A 2005-04-25 2006-04-25 Formulaciones de liberacion prolongada. MX2007013327A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67444405P 2005-04-25 2005-04-25
PCT/US2006/015373 WO2006116247A1 (en) 2005-04-25 2006-04-25 Extended release formulations

Publications (1)

Publication Number Publication Date
MX2007013327A true MX2007013327A (es) 2008-04-21

Family

ID=36698750

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007013327A MX2007013327A (es) 2005-04-25 2006-04-25 Formulaciones de liberacion prolongada.

Country Status (9)

Country Link
US (1) US20060275367A1 (es)
EP (1) EP1877040A1 (es)
JP (1) JP2008539240A (es)
AU (1) AU2006239838A1 (es)
BR (1) BRPI0610257A2 (es)
CA (1) CA2605792A1 (es)
MX (1) MX2007013327A (es)
RU (1) RU2007143556A (es)
WO (1) WO2006116247A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007122636A1 (en) * 2006-04-25 2007-11-01 Panacea Biotec Ltd Pharmaceutical compositions containing long chain fatty acids as excipients as well as a process for manufacturing the same
AU2014201170B2 (en) * 2006-12-20 2015-09-24 Mylan Pharmaceuticals Ulc Pharmaceutical composition comprising a hot-melt granulated lubricant
EP2114455A4 (en) * 2006-12-20 2010-03-17 Mylan Pharmaceuticals Ulc PHARMACEUTICAL COMPOSITION USING A HOT-MELT GRANULATED AGENT
EP1972336A1 (en) * 2007-03-19 2008-09-24 LEK Pharmaceuticals D.D. Hot-melt micropellets
KR101609279B1 (ko) * 2008-03-21 2016-04-05 밀란 파마슈티컬즈, 인코포레이티드 왁스를 포함하는 서방형 제형
WO2014011830A1 (en) 2012-07-12 2014-01-16 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
KR101812090B1 (ko) * 2012-09-27 2017-12-27 웬델 지. 멘도자 서방성 포타슘 시트레이트 왁스 매트릭스 정제의 제조 방법
WO2014152207A1 (en) * 2013-03-15 2014-09-25 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
WO2022266311A1 (en) * 2021-06-16 2022-12-22 Summit Biomedical Imaging PARPi-FL FORMULATIONS
CN117100711A (zh) * 2022-05-16 2023-11-24 江苏万珺医药科技有限公司 一种含有盐酸曲唑酮的缓释片剂及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2489439A (en) * 1947-06-27 1949-11-29 Samuel M Taylor Record controlled printing machine
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
USRE34990E (en) * 1986-08-07 1995-07-04 Ciba-Geigy Corporation Oral therapeutic system having systemic action
CH668187A5 (de) * 1986-08-07 1988-12-15 Ciba Geigy Ag Therapeutisches system mit systemischer wirkung.
ATE107854T1 (de) * 1988-09-30 1994-07-15 Rhone Poulenc Rorer Ltd Pharmazeutisches granulat.
US5169645A (en) * 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
TW209174B (es) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
ATE223704T1 (de) * 1992-10-16 2002-09-15 Nippon Shinyaku Co Ltd Verfahren zur herstellung von wachsmatrizes
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
DE4423078B4 (de) * 1994-07-01 2005-01-13 Awd.Pharma Gmbh & Co. Kg Verfahren zur Herstellung einer Carbamazepin-Arzneiform mit verzögerter Wirkstofffreisetzung
US5980942A (en) * 1997-01-23 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release matrix tablet formulations of carbamazepine
US6296873B1 (en) * 1997-01-23 2001-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release delivery system for carbamazephine derivatives
DE19729487A1 (de) * 1997-07-10 1999-01-14 Dresden Arzneimittel Verfahren zur Herstellung von Wirkstoff-Zubereitungen mit kontrollierter Freisetzung aus einer Matrix
DE19747261A1 (de) * 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
IL125244A (en) * 1998-07-07 2002-12-01 Yissum Res Dev Co Pharmaceutical compositions containing low-melting waxes
US6378526B1 (en) * 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US6162466A (en) * 1999-04-15 2000-12-19 Taro Pharmaceutical Industries Ltd. Sustained release formulation of carbamazepine
US20020015730A1 (en) * 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
ITMI20012749A1 (it) * 2001-12-21 2003-06-21 Chiesi Farma Spa Procedimento per la preparazione mediante trattamento con microonde di composti di inclusione tra farmaco e ciclodestrine e prodotti ottenut
US6572889B1 (en) * 2002-03-07 2003-06-03 Noveon Ip Holdings Corp. Controlled release solid dosage carbamazepine formulations
NZ542303A (en) * 2003-03-14 2008-12-24 Nirmal Mulye A process for preparing sustained release tablets
US20040241234A1 (en) * 2003-06-02 2004-12-02 Alpharma, Inc. Controlled release press-coated formulations of water-soluble active agents
EP1750717B1 (en) * 2004-02-11 2017-07-19 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
US20080075785A1 (en) * 2006-09-22 2008-03-27 San-Laung Chow Controlled release hydrogel formulation

Also Published As

Publication number Publication date
AU2006239838A1 (en) 2006-11-02
WO2006116247A1 (en) 2006-11-02
CA2605792A1 (en) 2006-11-02
RU2007143556A (ru) 2009-06-10
US20060275367A1 (en) 2006-12-07
EP1877040A1 (en) 2008-01-16
JP2008539240A (ja) 2008-11-13
BRPI0610257A2 (pt) 2010-06-08

Similar Documents

Publication Publication Date Title
WO2009117130A3 (en) Extended release forumulation containing a wax
MX2007014892A (es) Formas polimorficas del ester etilico del acido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}- 1-metil-h-bencimidazol-5-carbonil)-piridin-2-il--amino]propionico .
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
MX2008007307A (es) Granulos/capsulas modificados que contienen ingrediente activo.
ECSP088560A (es) Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido
MX2007005156A (es) Trehalosa y/o isomaltulosa como excipiente para formulaciones de aroma secas.
AP2441A (en) Low-faoming aqueous formulations used for crop protection
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
CR9786A (es) Compuestos de bencimidazol-tiofeno
BRPI0923728A2 (pt) "método de preparação de compostos de di-hidroindeno amida, suas composições farmacêuticas contendo esses compostos e uso como inibidor de proteína quinase".
DK1776010T3 (da) Fremgangsmåde til fremstilling af vandige aktivstofsammensætninger af aktivstoffer, som er tungt oplöselige i vand
UA103319C2 (en) Thiazole- and oxazole-benzene sulfonamide compounds
EA200701065A1 (ru) Инъецируемые составы, содержащие нанодисперсный оланзапин
EP2093237A4 (en) Cancer therapeutic agent comprising anti-hb-egf antibody as active ingredient
WO2010021607A3 (en) Pharmaceutical formulation
ATE530170T1 (de) Paliperidonformulierung mit verzögerter freisetzung
UA90875C2 (ru) Лекарственные формы пролонгированного действия, которые содержат ранолазин
WO2009105969A8 (zh) 埃坡霉素类似物、其药物组合物、用途及其制备方法
MX2007013327A (es) Formulaciones de liberacion prolongada.
MX2010008365A (es) Formulacion de liberacion sostenida que comprende octreotido y tres polimeros lineales de polilactido-co-glicolido.
TW200621160A (en) Anti-termite agent
FR2894143B1 (fr) Composition a liberation prolongee de l'actif, son procede de preparation et son utilisation.
DK1464341T3 (da) Ubiquinon-holdig, vandopløselig formulering til ophthalmisk anvendelse
WO2009151770A3 (en) Colchicine solid-state forms; methods of making; and methods of use thereof